Disease Reactivation in Secondary Progressive Multiple Sclerosis Patients Switching from Fingolimod to Siponimod: A Case Series

Siponimod, a selective modulator of sphingosine 1-phosphate receptors 1 (S1P1) and 5 (S1P5), has recently been marketed for patients with Secondary Progressive Multiple Sclerosis (SPMS). Herein, we report three SPMS patients presenting disease reactivation in the first three months after switching f...

Descripción completa

Detalles Bibliográficos
Autores principales: Abbadessa, Gianmarco, Maida, Elisabetta, Miele, Giuseppina, Bile, Floriana, Lavorgna, Luigi, Bonavita, Simona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9605018/
https://www.ncbi.nlm.nih.gov/pubmed/36294354
http://dx.doi.org/10.3390/jcm11206033
_version_ 1784817961251373056
author Abbadessa, Gianmarco
Maida, Elisabetta
Miele, Giuseppina
Bile, Floriana
Lavorgna, Luigi
Bonavita, Simona
author_facet Abbadessa, Gianmarco
Maida, Elisabetta
Miele, Giuseppina
Bile, Floriana
Lavorgna, Luigi
Bonavita, Simona
author_sort Abbadessa, Gianmarco
collection PubMed
description Siponimod, a selective modulator of sphingosine 1-phosphate receptors 1 (S1P1) and 5 (S1P5), has recently been marketed for patients with Secondary Progressive Multiple Sclerosis (SPMS). Herein, we report three SPMS patients presenting disease reactivation in the first three months after switching from fingolimod to siponimod. Fingolimod binds to S1P1, S1P3, S1P4 and S1P5 receptors. S1P3 holds a central role in eliciting central proinflammatory responses, thus it has been hypothesized that upregulation of S1P3 may be the mechanism behind relapses after switching from fingolimod to siponimod. Further studies are needed to investigate the safety and efficacy of this treatment sequencing.
format Online
Article
Text
id pubmed-9605018
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96050182022-10-27 Disease Reactivation in Secondary Progressive Multiple Sclerosis Patients Switching from Fingolimod to Siponimod: A Case Series Abbadessa, Gianmarco Maida, Elisabetta Miele, Giuseppina Bile, Floriana Lavorgna, Luigi Bonavita, Simona J Clin Med Case Report Siponimod, a selective modulator of sphingosine 1-phosphate receptors 1 (S1P1) and 5 (S1P5), has recently been marketed for patients with Secondary Progressive Multiple Sclerosis (SPMS). Herein, we report three SPMS patients presenting disease reactivation in the first three months after switching from fingolimod to siponimod. Fingolimod binds to S1P1, S1P3, S1P4 and S1P5 receptors. S1P3 holds a central role in eliciting central proinflammatory responses, thus it has been hypothesized that upregulation of S1P3 may be the mechanism behind relapses after switching from fingolimod to siponimod. Further studies are needed to investigate the safety and efficacy of this treatment sequencing. MDPI 2022-10-13 /pmc/articles/PMC9605018/ /pubmed/36294354 http://dx.doi.org/10.3390/jcm11206033 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Abbadessa, Gianmarco
Maida, Elisabetta
Miele, Giuseppina
Bile, Floriana
Lavorgna, Luigi
Bonavita, Simona
Disease Reactivation in Secondary Progressive Multiple Sclerosis Patients Switching from Fingolimod to Siponimod: A Case Series
title Disease Reactivation in Secondary Progressive Multiple Sclerosis Patients Switching from Fingolimod to Siponimod: A Case Series
title_full Disease Reactivation in Secondary Progressive Multiple Sclerosis Patients Switching from Fingolimod to Siponimod: A Case Series
title_fullStr Disease Reactivation in Secondary Progressive Multiple Sclerosis Patients Switching from Fingolimod to Siponimod: A Case Series
title_full_unstemmed Disease Reactivation in Secondary Progressive Multiple Sclerosis Patients Switching from Fingolimod to Siponimod: A Case Series
title_short Disease Reactivation in Secondary Progressive Multiple Sclerosis Patients Switching from Fingolimod to Siponimod: A Case Series
title_sort disease reactivation in secondary progressive multiple sclerosis patients switching from fingolimod to siponimod: a case series
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9605018/
https://www.ncbi.nlm.nih.gov/pubmed/36294354
http://dx.doi.org/10.3390/jcm11206033
work_keys_str_mv AT abbadessagianmarco diseasereactivationinsecondaryprogressivemultiplesclerosispatientsswitchingfromfingolimodtosiponimodacaseseries
AT maidaelisabetta diseasereactivationinsecondaryprogressivemultiplesclerosispatientsswitchingfromfingolimodtosiponimodacaseseries
AT mielegiuseppina diseasereactivationinsecondaryprogressivemultiplesclerosispatientsswitchingfromfingolimodtosiponimodacaseseries
AT bilefloriana diseasereactivationinsecondaryprogressivemultiplesclerosispatientsswitchingfromfingolimodtosiponimodacaseseries
AT lavorgnaluigi diseasereactivationinsecondaryprogressivemultiplesclerosispatientsswitchingfromfingolimodtosiponimodacaseseries
AT bonavitasimona diseasereactivationinsecondaryprogressivemultiplesclerosispatientsswitchingfromfingolimodtosiponimodacaseseries

Ejemplares similares